After years of US litigation with GlaxoSmithKline over a skinny-label generic version of the originator’s Coreg (carvedilol) and induced-infringement allegations, Teva has taken the battle to the highest court in the land by filing a petition for certiorari review with the country’s Supreme Court.
The question presented to the Supreme Court by the Israeli firm is: “If a generic drug’s US Food and Drug Administration-approved label carves out all of the language that the brand manufacturer has identified as covering its patented uses, can the generic manufacturer be held liable
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?